Aviceda Therapeutics
Biotechnology company developing glyco-immune checkpoint therapeutics to treat immune-mediated diseases. The company states a lead focus on therapies for macular degeneration and aims to develop novel treatments to improve patient outcomes.
Industries
Biotechnology
Health Care
Life Science
Neuroscience
Pharmaceutical
Therapeutics
Biotechnology Research
Nr. of Employees
small (1-50)
Aviceda Therapeutics
Products
AVD-104
A first-in-class glyco-immune checkpoint modulator and sialic acid coated nanoparticle designed for slowing the progress of dry age-related macular degeneration (AMD) and geographic atrophy.
Siglec Targeting Ligand Pulmonary
Research and development candidate targeting pulmonary diseases.
AVD-104
A first-in-class glyco-immune checkpoint modulator and sialic acid coated nanoparticle designed for slowing the progress of dry age-related macular degeneration (AMD) and geographic atrophy.
Siglec Targeting Ligand Pulmonary
Research and development candidate targeting pulmonary diseases.
Expertise Areas
- Glyco-immune checkpoint therapeutics
- Immune-mediated disease therapeutics
- Ophthalmic therapeutics (macular degeneration)
- Therapeutic discovery and development
Key Technologies
- Glyco-immune checkpoint modulation
- Immune checkpoint modulation